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I n t r o d u c t i o n. Over 80% of children treated for Hodgkin's disease (HD) acquire long-lasting event free survival; however,
oncological treatment is connected with multiple side effects.The aim of this study was to estimate the type and frequency of
acute complications of chemo- and radiotherapy in children with HD.
M a t e r i a l  a n d  m e t h o d s.  21 patients, aged 2.5 -17 years, treated for HD in the Department of Pediatrics, Hematology,
Oncology and Endocrinology, Medical University of Gdaƒsk according to Protocol HD-95 or HD-97 were analyzed retrospec-
tively. All of them achieved remission of neoplastic disease. We estimated incidence of hematological, infectious, gastric, he-
patic, pulmonary and cardiac side effects.
R e s u l t s.  Severe myelosupression (IV° toxicity according to WHO scale) was the most frequent side effect observed in
17/21 patients (80.9%). Infectious complications, mainly opportunistic, were observed in 13 children. Gastrotoxicity of mo-
derate intensity was observed in 6 children, predominantly after B-DOPA cycles. Hepatotoxicity was manifested as the incre-
ased aminotransferases serum levels. Only one patient with simultaneous hepatitis B infection demonstrated clinical symptoms
of liver disorder with jaundice and hepatomegaly. Cardiac complications were revealed by echocardiographical examinations
as a decreased ejection fraction of left ventricle (EF) in 6/21 children. Moreover one of them had pericardial effusion with ade-
quate clinical signs of circulatory failure. Pulmonary toxicity was recorded in chest radiography of the youngest (2.5-yrs.) girl
and was interpreted as pneumonia. The majority of all acute complications were transient and reversible, except for the fibro-
us changes in the lungs, which persisted.
C o n c l u s i o n s.  Multimodal oncological therapy of HD may require hematopoietic growth factors to realize the protocol wi-
thout delays brought on by severe neutropenia. The frequency of opportunistic infections calls for particular attention to pro-
per epidemiological conditions throughout therapy. It is indicated to monitor several organ functions because of various com-
plications, which may appear during and soon after the end of therapy.
Ostre powik∏ania leczenia choroby Hodgkina u dzieci
W p r o w a d z e n i e. W leczeniu choroby Hodgkina (HD) u dzieci osiàga si´ obecnie ponad 80% d∏ugoletnich prze˝yç wolnych
od zdarzeƒ, lecz stosowana terapia stwarza pewne problemy, zwiàzane z wyst´powaniem powik∏aƒ dotyczàcych ró˝nych na-
rzàdów.
Celem pracy by∏o okreÊlenie rodzaju i cz´stoÊci wyst´powania ostrych powik∏aƒ w czasie leczenia tej choroby u dzieci.
M a t e r i a ∏  stanowili pacjenci leczeni z powodu HD w Klinice Pediatrii, Hematologii, Onkologii i Endokrynologii AM
w Gdaƒsku, zgodnie z programem HD-97, w latach 1994-1997. Wszyscy chorzy (21 pacjentów) osiàgn´li remisj´ choroby.
Analizie poddano uboczne objawy hematologiczne, infekcyjne, gastrotoksyczne, pulmotoksyczne i kardiotoksyczne, które wy-
stàpi∏y w czasie prowadzonej chemio- i radioterapii.
W y n i k i. Najcz´Êciej (u 17 chorych) obserwowano objawy mielosupresji o znacznym nasileniu (IV° toksycznoÊci wg WHO).
Powik∏ania infekcyjne, g∏ównie infekcje oportunistyczne, wystàpi∏y u 13 pacjentów. Objawy gastrotoksyczne o miernym nasile-
niu pojawi∏y si´ u 6 dzieci po cyklach B-DOPA. HepatotoksycznoÊç, manifestujàca si´ wzrostem poziomu aminotransferaz,
stwierdzono u 6 badanych, a u 1 z nich stwierdzono kliniczne objawy z pojawieniem si´ ˝ó∏taczki. By∏ to chory – nosiciel anty-
genu HBs. Zmiany w badaniu echokardiograficznym serca, pod postacià obni˝onej frakcji wyrzutowej lewej komory, stwierdzo-
no u 6 pacjentów. W jednym przypadku stwierdzono te˝ obecnoÊç p∏ynu w worku osierdziowym, z towarzyszàcymi objawami kli-
nicznymi. Zmiany o charakterze pneumonitis stwierdzono badaniem rtg klatki piersiowej u najm∏odszej (2,5 letniej) chorej. Wi´k-
szoÊç objawów mia∏a charakter przemijajàcy i odwracalny. Jedynie powik∏ania p∏ucne wykazujà tendencj´ do w∏óknienia.
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Introduction
Currently over 80% of children treated for Hodgkin's dise-
ase acquire long-lasting event free survival. Therefore the
survivors' good quality of life has become such an impor-
tant issue [1, 2, 3, 4]. The complications of antitumour
treatment may either take the form of acute toxicity – du-
ring or directly after chemo- and radiotherapy, or of late
toxicity – even long after the end of oncological treatment
[5, 6].
The incidence of acute side effects of chemo- and ra-
diotherapy in children with Hodgkin's disease depends
mainly on the intensity of antitumour therapy, but is also
affected by the individual sensitivity of patients' tissues
and organs. Acute complications predominantly involve
organs characterised by a high proliferation rate and, in
most cases, are entirely reversible. In such organs as the
nervous system, the lungs and the heart, side effects of
chemo- and radiotherapy are usually long-lasting or irre-
versible. Further problems arise from an increased risk of
secondary neoplasm incidence in patients cured of Hodg-
kin's disease [7, 8].
Material and methods
The analyzed group consisted of 21 children with Hodgkin's di-
sease, treated in the Department of Pediatrics, Hematology,
Oncology and Endocrinology, Medical University of Gdaƒsk in
the period of 1994-1998.
The characteristics of patients are shown in Tab. I.
Mean age of the group was 12 years 2 months. The majori-
ty of children (57%) were boys. 11 patients (52%) presented
with clinical stage II. Nodular sclerosis (NS) histological type
predominated, as it was recognised in 14 patients. Mediastinal
bulky disease was stated at diagnosis in 3 children, of whom
one demonstrated serious dyspnea and life-threatening signs of
superior vena cava syndrome, which demanded the administra-
tion of steroids and cyclophosphamide before biopsy and histo-
pathological examination of enlarged mediastinal lymph nodes.
Among patients presenting with clinical stage IV the extra-
nodular sites involved were: lungs, bones, liver and spleen.
All patients were treated according to HD-95 or HD-97
protocols accepted by The Polish Pediatric Leukemia/Lympho-
ma Study Group. Chemotherapy cycles are summarized in Table
II. In 2 children with stage IV disease, it was necessary to institu-
te additional cycles of chemotherapy (dexaBEAM and CEP)
due to their unsatisfactory clinical response to treatment. In
both these cases we eventually observed a positive overall thera-
peutical effect.
Complete remission was achieved in 18 patients, while in
the case of the remaining 3 children radiological examination re-
vealed residual mediastinal lymph nodes. At follow-up these
nodes remained stable in size. All the biochemical markers use-
ful in assessing the activity of Hodgkin's disease proved negative.
Tab. II. Chemotherapy in patients with Hodgkin's disease
Number of cycles 4 5 6 7 8
Number of patients 3 5 5 1 7
additonal cycles applied in the treatment:
1. dexa BEAM - 1 patient
2. CEP - 1 patient
The radiotherapeutical procedures performed are presen-
ted in Table III.
Follow-up from the end of therapy was 15 mo. – 5.5 yrs.
W n i o s k i.  Obecnie prowadzona terapia HD u dzieci wymaga w wielu przypadkach stosowania czynników wzrostu, aby umo˝-
liwiç realizacj´ protoko∏u terapeutycznego bez opóênieƒ.
Cz´ste wyst´powanie infekcji oportunistycznych nakazuje szczególnà dba∏oÊç o warunki epidemiologiczne hospitalizacji.
Ze wzgl´du na stwierdzanà cz´stoÊç powik∏aƒ pozaszpikowych, dotyczàcych ró˝nych narzàdów, wskazane jest dok∏adne
monitorowanie funkcji tych narzàdów w czasie i po zakoƒczeniu leczenia.
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Tab. I. Characteristics of patients with Hodgkin's disease treated between 1994-1998 
Number of patients 21
boys 12
girls 9
< 5 years old 2 patients
Age 5 – 9 years old 4 patients
10 – 14 l years old 5 patients
> 14 years old 10 patients
Remision 18/21 patients
3/21 “bulky disease” in mediastinum
Histology NS MC LP LD
14 6 1 0
Clinical stage I II A II B III A III B IV A IV B
0 7 4 3 3 0 4
Involved
non-lymphatic Lungs Bones Liver Spleen
organs in stage IV 2 1 1 1
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Tab. III. Radiotherapy in patients with Hodgkin's disease
Field of radiotherapy Number of patients
Without RTX 2
Cervical lymph nodes 4
Mediastinal field 6
Supra- and subdiaphragmatic fields 9
Involved parts of lungs 2
Results
Acute toxicities observed during active oncological treat-
ment comprised hematological, hepatic, cardiac, infec-
tious and pulmonary complications.
Myelosupression was the most common complica-
tion, being observed in 17 out of 21 children (80.9%).
White blood cell count was affected in 13 patients
(61.9%), with severe neutropenia (grade IV according
to WHO scale) in most cases. It was necessary to admini-
ster hemopoietic growth factors (G-CSF or GM-CSF) in
these patients. Red blood cells were transfused in 6 chil-
dren (28.5%) with severe anemia. Severe thrombocytope-
nia (grade IV according to WHO scale) was observed
only in 2 patients (9.5%). In one case a very low platelet
count maintained for 30 days after the end of chemothe-
rapy. The other patient, a 16-year-old boy with Hodg-
kin's disease grade II, had been previously treated for 10
years because of idiopathic thrombocytopenic purpura.
His platelet count at admission was 12 G/L and so the
first chemotherapy cycle dose was reduced by 50% and
preceded by prednisone administered for several days.
The entire oncological treatment was administered wi-
thout further delays, and the patient achieved complete
remission.
Infectious complications occurred in 13 children.
Opportunistic infections of a mild and moderate clinical
course predominated. None of them caused treatment
delay.
Six out of 21 patients (28.5%) demonstrated gastro-
toxic side effects of chemotherapy with predominant inci-
dence of abdominal pain, vomiting, constipation and loss
of appetite. These complications were usually observed
after B-DOPA cycles, lasted for 3-7 days and, in majority
of cases (5/6 patients), were of moderate degree. There
was only one patient who demonstrated severe clinical
signs of paralytic ileus. All these symptoms normalised
after intensive therapeutic management involving paren-
teral nutrition and administration of gastric mucose pro-
tectors and agents normalizing intestinal peristalsis.
In 3 children (14.2%) there were mild signs of muco-
sitis (grade I or II according to WHO scale). They disap-
peared approx. 7 days after the chemotherapy cycles.
Hepatotoxic side effects were predominantly manife-
sted by an elevation of aminotransferases, without any
other clinical signs. Such was the case in 6 children
(28.5%), who demonstrated solitary rise in ALT and AST
values of 75 to 200 U/ml. Only one patient suffered from
more expressed hepatic complications with jaundice (to-
tal serum bilirubin level of 9 mg/dl) and hepatomegaly.
This boy had been diagnosed to have positive serum mar-
kers of hepatitis B at admission. Liver biopsy revealed
aggressive hepatitis type B, which eventually caused an 8-
-week delay in antitumor treatment.
Cardiological complications occurred in 6 children
(28.5%). They were demonstrated in ultrasound examina-
tions by a decrease of left ventricle (LV) ejection frac-
tion to 53-57% (normal range: 60-80%). These distur-
bances proved to be entirely reversible, normalising within
2 to 6 weeks. The patients were administered coenzyme
Q 10 to protect the cardiac muscle. In one patient, a 13-
-year-old girl, the cardiotoxic complications manifested
differently. She was diagnosed as stage IV HD with infil-
trations of the left lung. Because of incomplete remis-
sion after conventional chemotherapy, she was additional-
ly administered one cycle of dexaBEAM chemotherapy
and underwent radiotherapy covering mediastinal lymph
nodes and left lung infiltrations. Eventually clinical re-
mission with a residual mass in mediastinum was achieved
in this patient. However, the oncological treatment re-
sulted in clinical signs of circulatory failure, which were
observed directly after the end of therapy. Consecutive ul-
trasound examinations demonstrated a gradually incre-
asing pericardiac effusion. Administration of non-steroid
anti-inflammatory drugs brought no improvement. Howe-
ver a 2-month therapy with steroids resulted in the di-
sappearance of pericardial exudative. At present, 2 years
after the end of therapy, the patient remains in remis-
sion and in good clinical state. Her ultrasound examina-
tions show only a small amount of fluid in the pericar-
dium.
Pulmonotoxicity occurred only in one child, the
youngest of our patients (2 yr. 3 mo. old at the moment of
diagnosis of HD stage IIA). Directly after the end of the-
rapy, the girl demonstrated clinical and radiological si-
gns of interstitial pneumonitis resistant to multiple anti-
biotics. Infectious etiology, involving opportunistic infec-
tions, was excluded. We observed a very good response to
steroid therapy with complete normalization of clinical si-
gns and nearly entire resolving of radiological abnormali-
ties. The remaining radiological changes visible in the in-
ferior lobes of both lungs have been interpreted as fibro-
sis, which, to the best of our knowledge, may be
connected with bleomycin administrated to this patient.
Discussion and conclusions
Acute toxicities in children undergoing active treatment of
Hodgkin's disease are mainly reversible, but in some cases
may cause delays in the realization of chemotherapeutical
protocol. It was observed in our analysis that severe my-
elosupression was the most common acute side effect of
chemotherapy, but eventually proved to be short-lasting
and entirely reversible. We have observed that the admi-
nistration of colony stimulating factors shortened the pe-
riod of neutropenia in our patients, which is in unison
with the reports of other authors [9, 10, 11].
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One must stress the high incidence of opportunistic
infections in the analyzed group. This implies the necessi-
ty of providing adequate epidemiological conditions and
prophylactics of contacts with contagious diseases thro-
ughout treatment.
Cardiotoxic complications may result from both an-
thracyclin administration and radiotherapy of mediastinal
lymph nodes [12, 13, 14]. Since these factors may cumula-
te, it seems advisable to monitor patients in order to reve-
al early, clinically mute cardiotoxic side effects. The peri-
cardial exudative, which was observed in one patient did
not cause any signs of cardiac tamponade and proved en-
tirely reversible. However, there are well-known case re-
ports on exudative pericarditis resistant to treatment and
of life-threatening severity.
Pulmonary complications usually develop as a late
toxicity, and are usually related to bleomycin admini-
stration. We suggest that a younger age of patients (<5
years of age) may be an additional risk factor of pulmo-
notoxicity.
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